In this Issue:
Prognostic factors for patients with malignant ovarian germ cell tumours
Trebananib treatment for recurrent ovarian cancer
PARP inhibitor maintenance therapy in patients with platinum-sensitive recurrent serous ovarian cancer
Prognostic factors for stage I borderline ovarian tumours
Age-dependent clinical characteristics and outcome in borderline ovarian tumours
Molecular signatures as predictors of chemoresponse
Cytoreduction as a prognostic factor for advanced epithelial ovarian cancer
Oxaliplatin/doxorubicin therapy in patients with platinum-sensitive & platinum-resistant ovarian cancer
Electronic referral for genetic risk assessment in ovarian cancer
Symptom burden and treatment outcomes for patients with platinum resistant/refractory recurrent ovarian cancer
Please login below to download this issue (PDF)